Cambridge Investment Research Advisors Inc. Purchases 32,046 Shares of Merck & Company, Inc. (MRK)

Cambridge Investment Research Advisors Inc. lifted its position in shares of Merck & Company, Inc. (NYSE:MRK) by 16.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 221,741 shares of the company’s stock after buying an additional 32,046 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Merck & were worth $14,211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RB Capital Management LLC boosted its position in Merck & by 0.5% during the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after purchasing an additional 23 shares in the last quarter. Baystate Wealth Management LLC boosted its position in Merck & by 0.4% during the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after purchasing an additional 27 shares in the last quarter. Bath Savings Trust Co boosted its position in Merck & by 0.5% during the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after purchasing an additional 28 shares in the last quarter. Camelot Portfolios LLC boosted its position in Merck & by 0.4% during the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after purchasing an additional 33 shares in the last quarter. Finally, Stillwater Investment Management LLC boosted its position in Merck & by 0.8% during the second quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock valued at $296,000 after purchasing an additional 38 shares in the last quarter. 72.98% of the stock is currently owned by institutional investors and hedge funds.

Merck & Company, Inc. (NYSE:MRK) opened at $54.10 on Tuesday. Merck & Company, Inc. has a 12 month low of $53.63 and a 12 month high of $66.80. The stock has a market capitalization of $147,550.00, a PE ratio of 14.19, a PEG ratio of 2.38 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period last year, the business posted $1.07 earnings per share. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. research analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current year.

In related news, Director Thomas H. Glocer sold 5,000 shares of Merck & stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.25% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Cambridge Investment Research Advisors Inc. Purchases 32,046 Shares of Merck & Company, Inc. (MRK)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.com-unik.info/2017/11/21/cambridge-investment-research-advisors-inc-purchases-32046-shares-of-merck-company-inc-mrk.html.

A number of brokerages recently weighed in on MRK. J P Morgan Chase & Co set a $70.00 price objective on Merck & and gave the company a “buy” rating in a research report on Sunday, October 29th. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & in a research report on Wednesday, November 1st. Sanford C. Bernstein reaffirmed a “buy” rating and set a $64.00 price objective on shares of Merck & in a research report on Wednesday, November 15th. BMO Capital Markets set a $70.00 price objective on Merck & and gave the company a “buy” rating in a research report on Wednesday, October 18th. Finally, Zacks Investment Research downgraded Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $66.87.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit